Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2022

View Archived Issues

THR-beta agonists described by Shanghai Kunheng Pharmaceutical Technology, Kunming Pharmaceutical

Shanghai Institute of Materia Medica identifies new nagilactone derivatives

New SOS-1 inhibitors discovered at Chengdu Baiyu Pharmaceutical

Discovery of allosteric mutant-selective EGFR inhibitor for the treatment of NSCLC

Sarissa presents new DNA repair protein RAD51 homolog 1 inhibitors

New CDC7 inhibitors synthesized at Medshine Discovery

FDA accepts IND for HOOKIPA's arenaviral immunotherapy HB-300 for metastatic CRPC

Altamira Therapeutics to develop OligoPhore-based AM-411 for rheumatoid arthritis

PsychoGenics to evaluate preclinical antiseizure efficacy of IAMA's selective NKCC1 inhibitors

Oryzon collaborates with CMTRF to evaluate HDAC6 inhibitors for Charcot-Marie-Tooth disease

RNF31 as a novel therapeutic target for immunotherapy-refractory cancers

New compound advances anoctamin-1 inhibition for analgesia

Nonessential but critical, tyrosine plays key role in nutrient sensing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...